 Rangaraj Selvarangan
Concepts (510)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 29 | 2024 | 68 | 8.890 |
Why?
| | Respiratory Tract Infections | 24 | 2024 | 85 | 7.920 |
Why?
| | Parechovirus | 16 | 2024 | 20 | 7.770 |
Why?
| | Enterovirus Infections | 19 | 2023 | 37 | 7.740 |
Why?
| | Picornaviridae Infections | 15 | 2024 | 21 | 7.490 |
Why?
| | Molecular Diagnostic Techniques | 16 | 2024 | 38 | 6.080 |
Why?
| | Infant | 99 | 2024 | 1446 | 6.010 |
Why?
| | Respiratory Syncytial Virus Infections | 17 | 2024 | 50 | 5.860 |
Why?
| | Humans | 173 | 2024 | 6896 | 5.720 |
Why?
| | Influenza A virus | 12 | 2023 | 20 | 5.450 |
Why?
| | Child | 108 | 2024 | 3364 | 4.950 |
Why?
| | Respiratory Syncytial Virus, Human | 12 | 2024 | 27 | 4.760 |
Why?
| | Influenza B virus | 13 | 2023 | 22 | 4.540 |
Why?
| | Gastroenteritis | 18 | 2024 | 28 | 4.520 |
Why?
| | Child, Preschool | 85 | 2024 | 1569 | 4.420 |
Why?
| | Enterovirus | 8 | 2023 | 12 | 4.210 |
Why?
| | Enterovirus D, Human | 12 | 2023 | 25 | 4.100 |
Why?
| | Nucleic Acid Amplification Techniques | 6 | 2020 | 13 | 3.540 |
Why?
| | United States | 55 | 2024 | 669 | 3.180 |
Why?
| | Sensitivity and Specificity | 31 | 2024 | 150 | 3.100 |
Why?
| | Female | 82 | 2024 | 3525 | 3.070 |
Why?
| | Male | 77 | 2024 | 3337 | 3.030 |
Why?
| | Anti-Bacterial Agents | 18 | 2023 | 243 | 3.020 |
Why?
| | Disease Outbreaks | 12 | 2023 | 29 | 2.920 |
Why?
| | Rotavirus Infections | 13 | 2024 | 20 | 2.810 |
Why?
| | Infant, Newborn | 40 | 2024 | 816 | 2.750 |
Why?
| | Rotavirus Vaccines | 10 | 2024 | 14 | 2.740 |
Why?
| | Adolescent | 56 | 2024 | 2197 | 2.710 |
Why?
| | Hospitalization | 27 | 2024 | 210 | 2.640 |
Why?
| | Prospective Studies | 34 | 2024 | 525 | 2.410 |
Why?
| | Feces | 18 | 2023 | 37 | 2.400 |
Why?
| | Real-Time Polymerase Chain Reaction | 10 | 2023 | 41 | 2.340 |
Why?
| | Central Nervous System Infections | 3 | 2021 | 5 | 2.310 |
Why?
| | Diagnostic Tests, Routine | 5 | 2019 | 19 | 2.260 |
Why?
| | Rotavirus | 10 | 2024 | 18 | 2.170 |
Why?
| | Nasopharynx | 12 | 2023 | 25 | 2.100 |
Why?
| | Antibodies, Viral | 11 | 2022 | 47 | 1.990 |
Why?
| | Norovirus | 5 | 2023 | 7 | 1.970 |
Why?
| | Bacteremia | 5 | 2021 | 25 | 1.850 |
Why?
| | Streptococcal Infections | 4 | 2020 | 19 | 1.830 |
Why?
| | Virus Diseases | 4 | 2024 | 16 | 1.740 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 10 | 2020 | 71 | 1.730 |
Why?
| | Reagent Kits, Diagnostic | 9 | 2018 | 13 | 1.650 |
Why?
| | Influenza Vaccines | 8 | 2024 | 28 | 1.610 |
Why?
| | Emergency Service, Hospital | 10 | 2024 | 130 | 1.550 |
Why?
| | Young Adult | 20 | 2024 | 647 | 1.510 |
Why?
| | Virology | 5 | 2015 | 5 | 1.510 |
Why?
| | Adult | 26 | 2024 | 1181 | 1.500 |
Why?
| | Pneumonia, Mycoplasma | 6 | 2024 | 15 | 1.480 |
Why?
| | Urinary Tract Infections | 3 | 2021 | 21 | 1.470 |
Why?
| | Polymerase Chain Reaction | 7 | 2019 | 84 | 1.380 |
Why?
| | Seasons | 13 | 2024 | 35 | 1.360 |
Why?
| | Bacteriological Techniques | 5 | 2021 | 7 | 1.350 |
Why?
| | Point-of-Care Testing | 2 | 2020 | 3 | 1.340 |
Why?
| | DNA, Viral | 4 | 2020 | 13 | 1.340 |
Why?
| | Sepsis | 4 | 2018 | 23 | 1.300 |
Why?
| | Middle Aged | 16 | 2021 | 608 | 1.270 |
Why?
| | Mycoplasma pneumoniae | 5 | 2020 | 12 | 1.250 |
Why?
| | Aged | 13 | 2021 | 378 | 1.230 |
Why?
| | Genotype | 18 | 2024 | 410 | 1.230 |
Why?
| | Retrospective Studies | 20 | 2023 | 1296 | 1.220 |
Why?
| | Clostridium Infections | 3 | 2020 | 7 | 1.210 |
Why?
| | Aged, 80 and over | 10 | 2021 | 151 | 1.180 |
Why?
| | Enterobacteriaceae Infections | 3 | 2023 | 10 | 1.170 |
Why?
| | Staphylococcal Infections | 4 | 2016 | 21 | 1.140 |
Why?
| | Specimen Handling | 5 | 2021 | 17 | 1.140 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2023 | 11 | 1.140 |
Why?
| | Enterobacteriaceae | 3 | 2023 | 7 | 1.130 |
Why?
| | Staphylococcus aureus | 3 | 2016 | 18 | 1.130 |
Why?
| | Escherichia coli | 12 | 2023 | 30 | 1.070 |
Why?
| | Respiratory System | 3 | 2015 | 5 | 1.060 |
Why?
| | Cerebrospinal Fluid | 4 | 2020 | 8 | 1.050 |
Why?
| | Missouri | 10 | 2024 | 81 | 1.030 |
Why?
| | Immunoassay | 4 | 2015 | 10 | 1.030 |
Why?
| | Point-of-Care Systems | 3 | 2020 | 10 | 1.010 |
Why?
| | Multiplex Polymerase Chain Reaction | 3 | 2022 | 9 | 1.010 |
Why?
| | Influenza A Virus, H1N1 Subtype | 5 | 2024 | 13 | 1.010 |
Why?
| | Cephalosporins | 3 | 2023 | 15 | 1.010 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2020 | 50 | 1.000 |
Why?
| | Rhinovirus | 4 | 2023 | 11 | 0.990 |
Why?
| | Antibodies, Neutralizing | 5 | 2022 | 31 | 0.980 |
Why?
| | Microbial Sensitivity Tests | 13 | 2023 | 33 | 0.980 |
Why?
| | Bodily Secretions | 2 | 2015 | 3 | 0.970 |
Why?
| | Antiviral Agents | 5 | 2024 | 30 | 0.970 |
Why?
| | Prevalence | 12 | 2023 | 146 | 0.950 |
Why?
| | Caliciviridae Infections | 3 | 2021 | 4 | 0.940 |
Why?
| | Streptococcus pyogenes | 3 | 2020 | 13 | 0.920 |
Why?
| | Coinfection | 2 | 2024 | 7 | 0.890 |
Why?
| | Vancomycin Resistance | 2 | 2014 | 4 | 0.880 |
Why?
| | Severity of Illness Index | 8 | 2024 | 149 | 0.880 |
Why?
| | Dysentery, Bacillary | 1 | 2023 | 2 | 0.870 |
Why?
| | Shigella | 1 | 2023 | 2 | 0.870 |
Why?
| | Respiratory Syncytial Viruses | 3 | 2024 | 18 | 0.860 |
Why?
| | Pseudomonas Infections | 1 | 2023 | 7 | 0.860 |
Why?
| | Cystic Fibrosis | 1 | 2023 | 18 | 0.860 |
Why?
| | Inpatients | 3 | 2020 | 44 | 0.850 |
Why?
| | Pandemics | 8 | 2024 | 82 | 0.830 |
Why?
| | Automation, Laboratory | 2 | 2019 | 4 | 0.830 |
Why?
| | Time Factors | 9 | 2020 | 250 | 0.820 |
Why?
| | Population Surveillance | 6 | 2021 | 13 | 0.820 |
Why?
| | Pharyngitis | 2 | 2020 | 16 | 0.800 |
Why?
| | Viral Vaccines | 3 | 2022 | 10 | 0.800 |
Why?
| | Itraconazole | 2 | 2020 | 2 | 0.790 |
Why?
| | Triazoles | 2 | 2020 | 3 | 0.790 |
Why?
| | Clinical Laboratory Techniques | 5 | 2021 | 9 | 0.770 |
Why?
| | Asthma | 2 | 2023 | 157 | 0.770 |
Why?
| | Mass Screening | 2 | 2019 | 35 | 0.770 |
Why?
| | Bacterial Infections | 1 | 2021 | 27 | 0.760 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 23 | 0.750 |
Why?
| | Phlebotomy | 2 | 2011 | 3 | 0.740 |
Why?
| | Equipment Contamination | 2 | 2011 | 6 | 0.740 |
Why?
| | Phylogeny | 10 | 2022 | 24 | 0.740 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2020 | 4 | 0.730 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 3 | 0.720 |
Why?
| | Vaccination | 12 | 2024 | 71 | 0.720 |
Why?
| | Antigens, Viral | 4 | 2022 | 8 | 0.720 |
Why?
| | Kansas | 4 | 2023 | 43 | 0.710 |
Why?
| | Drug Utilization | 2 | 2024 | 15 | 0.710 |
Why?
| | RNA Viruses | 1 | 2019 | 3 | 0.700 |
Why?
| | Urinalysis | 1 | 2019 | 4 | 0.690 |
Why?
| | Case-Control Studies | 12 | 2024 | 215 | 0.690 |
Why?
| | Communicable Diseases, Emerging | 1 | 2019 | 3 | 0.670 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2019 | 6 | 0.670 |
Why?
| | Risk Factors | 9 | 2024 | 487 | 0.660 |
Why?
| | Peritonitis | 2 | 2021 | 58 | 0.650 |
Why?
| | Molecular Typing | 1 | 2018 | 1 | 0.640 |
Why?
| | Paramyxoviridae Infections | 2 | 2022 | 12 | 0.610 |
Why?
| | Bordetella Infections | 2 | 2014 | 2 | 0.600 |
Why?
| | Bordetella parapertussis | 2 | 2014 | 2 | 0.600 |
Why?
| | Peritoneal Dialysis | 2 | 2021 | 158 | 0.590 |
Why?
| | Escherichia coli Infections | 7 | 2017 | 19 | 0.580 |
Why?
| | Carrier State | 2 | 2018 | 5 | 0.570 |
Why?
| | Adhesins, Escherichia coli | 9 | 2017 | 9 | 0.560 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 5 | 2016 | 16 | 0.550 |
Why?
| | Schools | 4 | 2024 | 56 | 0.540 |
Why?
| | Fever | 4 | 2021 | 26 | 0.540 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 13 | 0.520 |
Why?
| | Drug Resistance, Bacterial | 5 | 2020 | 14 | 0.520 |
Why?
| | Sequence Analysis, DNA | 7 | 2019 | 115 | 0.520 |
Why?
| | Herpes Simplex | 2 | 2020 | 10 | 0.510 |
Why?
| | RNA, Viral | 3 | 2015 | 13 | 0.510 |
Why?
| | Pharynx | 3 | 2020 | 7 | 0.510 |
Why?
| | Mycoplasma | 1 | 2015 | 2 | 0.500 |
Why?
| | Mycoplasma Infections | 1 | 2015 | 2 | 0.500 |
Why?
| | Antigens, Bacterial | 3 | 2011 | 9 | 0.500 |
Why?
| | Bordetella pertussis | 1 | 2014 | 1 | 0.490 |
Why?
| | Spike Glycoprotein, Coronavirus | 4 | 2022 | 19 | 0.490 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 2 | 0.480 |
Why?
| | Viruses | 3 | 2022 | 5 | 0.480 |
Why?
| | Blood Specimen Collection | 2 | 2011 | 5 | 0.470 |
Why?
| | Macrolides | 5 | 2020 | 9 | 0.470 |
Why?
| | Vancomycin | 1 | 2014 | 17 | 0.460 |
Why?
| | Adenovirus Infections, Human | 2 | 2011 | 4 | 0.460 |
Why?
| | Animals | 12 | 2022 | 729 | 0.460 |
Why?
| | Virus Cultivation | 4 | 2015 | 4 | 0.460 |
Why?
| | Saliva | 3 | 2023 | 10 | 0.460 |
Why?
| | Candida | 2 | 2003 | 3 | 0.450 |
Why?
| | Acute Disease | 6 | 2024 | 79 | 0.450 |
Why?
| | Vaccines | 2 | 2023 | 17 | 0.420 |
Why?
| | Metapneumovirus | 2 | 2022 | 12 | 0.420 |
Why?
| | Genetic Variation | 3 | 2022 | 174 | 0.420 |
Why?
| | International Classification of Diseases | 2 | 2024 | 10 | 0.420 |
Why?
| | Enterococcus | 1 | 2012 | 3 | 0.410 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2012 | 8 | 0.410 |
Why?
| | Paramyxoviridae | 1 | 2011 | 1 | 0.410 |
Why?
| | Streptococcus bovis | 1 | 2011 | 1 | 0.400 |
Why?
| | Meningitis, Bacterial | 1 | 2011 | 4 | 0.400 |
Why?
| | Oligonucleotide Probes | 2 | 2009 | 4 | 0.390 |
Why?
| | Influenza A Virus, H3N2 Subtype | 5 | 2023 | 12 | 0.390 |
Why?
| | Campylobacter Infections | 1 | 2011 | 2 | 0.390 |
Why?
| | False Positive Reactions | 1 | 2011 | 4 | 0.390 |
Why?
| | Adenoviruses, Human | 1 | 2011 | 2 | 0.380 |
Why?
| | Blood | 1 | 2011 | 10 | 0.380 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 11 | 0.380 |
Why?
| | Catheterization, Peripheral | 1 | 2011 | 5 | 0.380 |
Why?
| | Follow-Up Studies | 5 | 2021 | 304 | 0.370 |
Why?
| | Meningitis, Viral | 2 | 2022 | 2 | 0.370 |
Why?
| | Pediatric Nursing | 1 | 2010 | 5 | 0.360 |
Why?
| | Infection Control | 1 | 2010 | 7 | 0.360 |
Why?
| | Respiratory Syncytial Virus Vaccines | 3 | 2024 | 8 | 0.350 |
Why?
| | Genotyping Techniques | 2 | 2020 | 22 | 0.350 |
Why?
| | Pyelonephritis | 4 | 2004 | 5 | 0.340 |
Why?
| | Epidemiological Monitoring | 5 | 2021 | 5 | 0.340 |
Why?
| | Encephalitis, Viral | 1 | 2009 | 1 | 0.330 |
Why?
| | Simplexvirus | 1 | 2009 | 3 | 0.330 |
Why?
| | Haemophilus influenzae | 1 | 2009 | 4 | 0.330 |
Why?
| | Streptococcus pneumoniae | 1 | 2009 | 5 | 0.330 |
Why?
| | Antifungal Agents | 2 | 2020 | 13 | 0.330 |
Why?
| | Cohort Studies | 5 | 2024 | 289 | 0.330 |
Why?
| | Mycobacterium | 2 | 2010 | 2 | 0.330 |
Why?
| | Hospitals, Pediatric | 5 | 2024 | 187 | 0.310 |
Why?
| | Predictive Value of Tests | 4 | 2019 | 99 | 0.300 |
Why?
| | Adhesins, Bacterial | 2 | 2004 | 2 | 0.290 |
Why?
| | Reproducibility of Results | 3 | 2012 | 199 | 0.290 |
Why?
| | beta-Lactamases | 3 | 2018 | 6 | 0.280 |
Why?
| | Students | 2 | 2024 | 34 | 0.280 |
Why?
| | Candida albicans | 2 | 2003 | 4 | 0.270 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 23 | 0.260 |
Why?
| | Fucosyltransferases | 2 | 2015 | 2 | 0.260 |
Why?
| | Algorithms | 3 | 2020 | 105 | 0.260 |
Why?
| | Risk Assessment | 3 | 2024 | 137 | 0.250 |
Why?
| | Cluster Analysis | 4 | 2015 | 43 | 0.250 |
Why?
| | Immunity, Humoral | 2 | 2022 | 14 | 0.250 |
Why?
| | Immunization Programs | 2 | 2019 | 6 | 0.250 |
Why?
| | Cross Infection | 2 | 2017 | 12 | 0.250 |
Why?
| | Collagen Type IV | 1 | 2004 | 3 | 0.240 |
Why?
| | Escherichia coli Proteins | 1 | 2004 | 3 | 0.240 |
Why?
| | Fimbriae, Bacterial | 4 | 2001 | 4 | 0.240 |
Why?
| | Cephalosporin Resistance | 3 | 2018 | 4 | 0.240 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 34 | 0.230 |
Why?
| | Cytomegalovirus Infections | 1 | 2023 | 3 | 0.220 |
Why?
| | Azithromycin | 1 | 2023 | 5 | 0.220 |
Why?
| | Longitudinal Studies | 2 | 2020 | 119 | 0.220 |
Why?
| | Penicillanic Acid | 1 | 2023 | 2 | 0.220 |
Why?
| | Pseudomonas aeruginosa | 1 | 2023 | 7 | 0.220 |
Why?
| | DNA Probes | 1 | 2002 | 1 | 0.220 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 14 | 0.210 |
Why?
| | Oseltamivir | 2 | 2021 | 6 | 0.210 |
Why?
| | Coronavirus | 1 | 2022 | 2 | 0.210 |
Why?
| | Viral Fusion Proteins | 1 | 2022 | 4 | 0.210 |
Why?
| | Seroepidemiologic Studies | 2 | 2019 | 3 | 0.210 |
Why?
| | Craniocerebral Trauma | 1 | 2022 | 18 | 0.210 |
Why?
| | Midwestern United States | 2 | 2013 | 34 | 0.200 |
Why?
| | Child, Hospitalized | 3 | 2022 | 26 | 0.200 |
Why?
| | Critical Care | 3 | 2018 | 13 | 0.200 |
Why?
| | Herpesvirus 1, Cercopithecine | 1 | 2021 | 2 | 0.200 |
Why?
| | Central Nervous System | 1 | 2021 | 9 | 0.200 |
Why?
| | Nasal Mucosa | 1 | 2021 | 8 | 0.200 |
Why?
| | Lung Diseases | 1 | 2021 | 23 | 0.200 |
Why?
| | Child Abuse | 1 | 2022 | 46 | 0.200 |
Why?
| | Cloud Computing | 1 | 2021 | 4 | 0.190 |
Why?
| | Disease Management | 2 | 2018 | 34 | 0.190 |
Why?
| | Lymphadenitis | 2 | 2013 | 3 | 0.190 |
Why?
| | Public Health Surveillance | 1 | 2020 | 4 | 0.190 |
Why?
| | Klebsiella Infections | 2 | 2017 | 3 | 0.190 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 36 | 0.180 |
Why?
| | ROC Curve | 1 | 2020 | 22 | 0.180 |
Why?
| | Coronavirus Infections | 1 | 2020 | 15 | 0.180 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 16 | 0.180 |
Why?
| | Quebec | 1 | 2020 | 4 | 0.180 |
Why?
| | Drug Resistance, Viral | 1 | 2020 | 2 | 0.180 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2020 | 2 | 0.180 |
Why?
| | Gastrointestinal Diseases | 1 | 2021 | 45 | 0.180 |
Why?
| | DNA, Bacterial | 3 | 2011 | 5 | 0.180 |
Why?
| | Canada | 1 | 2020 | 31 | 0.180 |
Why?
| | Herpesvirus 1, Human | 1 | 2020 | 4 | 0.180 |
Why?
| | Mouth | 1 | 2020 | 3 | 0.180 |
Why?
| | Family Health | 1 | 2020 | 14 | 0.180 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 23 | 0.180 |
Why?
| | Early Diagnosis | 1 | 2020 | 17 | 0.180 |
Why?
| | Postoperative Care | 1 | 2020 | 30 | 0.180 |
Why?
| | Europe | 1 | 2020 | 37 | 0.180 |
Why?
| | Immunoenzyme Techniques | 1 | 2019 | 9 | 0.170 |
Why?
| | Age Distribution | 1 | 2019 | 31 | 0.170 |
Why?
| | Prognosis | 1 | 2020 | 211 | 0.170 |
Why?
| | Gonorrhea | 2 | 2015 | 4 | 0.170 |
Why?
| | Molecular Epidemiology | 3 | 2017 | 6 | 0.170 |
Why?
| | History, 21st Century | 1 | 2019 | 6 | 0.170 |
Why?
| | Chronic Disease | 3 | 2012 | 105 | 0.170 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 3 | 0.170 |
Why?
| | Bacterial Typing Techniques | 2 | 2016 | 4 | 0.170 |
Why?
| | Immunization Schedule | 1 | 2019 | 10 | 0.160 |
Why?
| | Critical Pathways | 1 | 2018 | 8 | 0.160 |
Why?
| | Hematologic Diseases | 1 | 2018 | 4 | 0.160 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 9 | 0.160 |
Why?
| | False Negative Reactions | 1 | 2018 | 9 | 0.160 |
Why?
| | Vaccines, Attenuated | 4 | 2022 | 8 | 0.160 |
Why?
| | Intestines | 1 | 2018 | 29 | 0.160 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2017 | 2 | 0.150 |
Why?
| | Sapovirus | 1 | 2017 | 1 | 0.150 |
Why?
| | Cells, Cultured | 1 | 2017 | 84 | 0.150 |
Why?
| | Cell Line | 1 | 2017 | 81 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 94 | 0.150 |
Why?
| | Klebsiella pneumoniae | 1 | 2017 | 2 | 0.150 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 30 | 0.140 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 108 | 0.140 |
Why?
| | Staphylococcal Skin Infections | 1 | 2016 | 3 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 231 | 0.140 |
Why?
| | Clindamycin | 1 | 2016 | 3 | 0.140 |
Why?
| | Length of Stay | 2 | 2018 | 233 | 0.140 |
Why?
| | Neoplasms | 1 | 2018 | 128 | 0.140 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 336 | 0.130 |
Why?
| | Recombination, Genetic | 1 | 2015 | 5 | 0.130 |
Why?
| | Virulence Factors | 1 | 2015 | 4 | 0.130 |
Why?
| | C-Reactive Protein | 1 | 2015 | 16 | 0.130 |
Why?
| | Hemoglobins | 1 | 2015 | 27 | 0.130 |
Why?
| | Adenoviridae | 2 | 2022 | 6 | 0.130 |
Why?
| | Chlamydia trachomatis | 1 | 2015 | 2 | 0.130 |
Why?
| | Trichomonas Vaginitis | 1 | 2015 | 2 | 0.130 |
Why?
| | Chlamydia Infections | 1 | 2015 | 3 | 0.130 |
Why?
| | Dogs | 1 | 2015 | 17 | 0.120 |
Why?
| | Equipment Failure | 1 | 2015 | 10 | 0.120 |
Why?
| | Treatment Outcome | 5 | 2018 | 622 | 0.120 |
Why?
| | DNA, Ribosomal | 2 | 2011 | 3 | 0.120 |
Why?
| | Unnecessary Procedures | 1 | 2015 | 13 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2011 | 9 | 0.120 |
Why?
| | Quality Improvement | 1 | 2015 | 60 | 0.120 |
Why?
| | HeLa Cells | 6 | 2004 | 17 | 0.120 |
Why?
| | Age Factors | 3 | 2021 | 210 | 0.120 |
Why?
| | Base Sequence | 2 | 2004 | 81 | 0.110 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 71 | 0.110 |
Why?
| | DNA, Fungal | 2 | 2003 | 6 | 0.110 |
Why?
| | Mice | 3 | 2022 | 348 | 0.110 |
Why?
| | Abscess | 1 | 2013 | 10 | 0.110 |
Why?
| | Viral Proteins | 1 | 2013 | 8 | 0.110 |
Why?
| | Incidence | 2 | 2011 | 133 | 0.110 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 11 | 0.110 |
Why?
| | Diarrhea | 2 | 2011 | 18 | 0.110 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 21 | 0.110 |
Why?
| | Pneumococcal Infections | 2 | 2011 | 6 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 5 | 0.100 |
Why?
| | Immunity, Cellular | 2 | 2022 | 18 | 0.100 |
Why?
| | RNA, Messenger | 2 | 2023 | 115 | 0.100 |
Why?
| | Pregnancy | 5 | 2024 | 216 | 0.100 |
Why?
| | Epitopes | 2 | 2022 | 20 | 0.100 |
Why?
| | Enterotoxins | 1 | 2011 | 2 | 0.100 |
Why?
| | Exudates and Transudates | 1 | 2011 | 1 | 0.100 |
Why?
| | Middle Ear Ventilation | 1 | 2011 | 1 | 0.100 |
Why?
| | Operon | 3 | 2001 | 3 | 0.100 |
Why?
| | Campylobacter | 1 | 2011 | 2 | 0.100 |
Why?
| | Communicable Diseases | 1 | 2011 | 8 | 0.100 |
Why?
| | Serotyping | 1 | 2011 | 1 | 0.100 |
Why?
| | Restriction Mapping | 1 | 2011 | 6 | 0.100 |
Why?
| | Epidemiologic Methods | 1 | 2011 | 2 | 0.100 |
Why?
| | Policy Making | 1 | 2011 | 3 | 0.100 |
Why?
| | Immunocompromised Host | 2 | 2020 | 10 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2010 | 13 | 0.090 |
Why?
| | Cost of Illness | 2 | 2020 | 19 | 0.090 |
Why?
| | Linear Models | 1 | 2010 | 56 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2011 | 184 | 0.090 |
Why?
| | Disease Models, Animal | 3 | 2005 | 71 | 0.090 |
Why?
| | Databases, Factual | 1 | 2010 | 108 | 0.090 |
Why?
| | Moraxellaceae Infections | 1 | 2009 | 1 | 0.080 |
Why?
| | Haemophilus Infections | 1 | 2009 | 5 | 0.080 |
Why?
| | Parents | 2 | 2021 | 157 | 0.080 |
Why?
| | Bacterial Proteins | 3 | 2017 | 8 | 0.080 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2010 | 40 | 0.080 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2008 | 2 | 0.080 |
Why?
| | Mutation | 3 | 2019 | 212 | 0.080 |
Why?
| | Biomarkers | 2 | 2021 | 136 | 0.080 |
Why?
| | DNA, Ribosomal Spacer | 2 | 2010 | 3 | 0.080 |
Why?
| | Temperature | 2 | 2010 | 12 | 0.080 |
Why?
| | Virulence | 2 | 2004 | 7 | 0.070 |
Why?
| | Mycobacterium Infections | 1 | 2006 | 1 | 0.070 |
Why?
| | Mice, Inbred C3H | 2 | 2004 | 6 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2006 | 17 | 0.070 |
Why?
| | Illinois | 2 | 2015 | 5 | 0.060 |
Why?
| | Absenteeism | 1 | 2024 | 2 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 24 | 0.060 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2001 | 17 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 8 | 0.060 |
Why?
| | Chromatography, Gas | 1 | 2004 | 1 | 0.060 |
Why?
| | Fatty Acids | 1 | 2004 | 2 | 0.060 |
Why?
| | Hospital Costs | 1 | 2024 | 29 | 0.060 |
Why?
| | Candida glabrata | 1 | 2003 | 1 | 0.060 |
Why?
| | Culture Media | 1 | 2003 | 2 | 0.060 |
Why?
| | Mycology | 1 | 2003 | 2 | 0.060 |
Why?
| | Gene Amplification | 1 | 2003 | 4 | 0.060 |
Why?
| | CHO Cells | 2 | 2002 | 3 | 0.060 |
Why?
| | Cricetinae | 2 | 2002 | 4 | 0.060 |
Why?
| | Health Care Costs | 1 | 2024 | 33 | 0.060 |
Why?
| | Research Design | 1 | 2024 | 63 | 0.060 |
Why?
| | DNA Primers | 1 | 2003 | 30 | 0.060 |
Why?
| | Kidney | 1 | 2004 | 94 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 65 | 0.060 |
Why?
| | Mothers | 1 | 2024 | 33 | 0.060 |
Why?
| | Acceleration | 1 | 2023 | 4 | 0.060 |
Why?
| | Cytomegalovirus | 1 | 2023 | 2 | 0.060 |
Why?
| | Neonatal Screening | 1 | 2023 | 7 | 0.060 |
Why?
| | Cross-Over Studies | 1 | 2023 | 35 | 0.060 |
Why?
| | Educational Status | 1 | 2023 | 21 | 0.050 |
Why?
| | Antibody Affinity | 1 | 2022 | 4 | 0.050 |
Why?
| | Mycological Typing Techniques | 1 | 2002 | 3 | 0.050 |
Why?
| | Candidiasis | 1 | 2002 | 5 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2022 | 15 | 0.050 |
Why?
| | Oxygen | 1 | 2022 | 14 | 0.050 |
Why?
| | Phenotype | 1 | 2004 | 257 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 9 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2002 | 5 | 0.050 |
Why?
| | Macaca nemestrina | 1 | 2002 | 1 | 0.050 |
Why?
| | Trypanosoma cruzi | 1 | 2002 | 2 | 0.050 |
Why?
| | Chagas Disease | 1 | 2002 | 2 | 0.050 |
Why?
| | Hematoma, Subdural | 1 | 2022 | 4 | 0.050 |
Why?
| | Microbiological Techniques | 2 | 2015 | 5 | 0.050 |
Why?
| | Hospitals | 1 | 2022 | 36 | 0.050 |
Why?
| | Viral Load | 1 | 2021 | 14 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2021 | 16 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 7 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2021 | 31 | 0.050 |
Why?
| | Epitope Mapping | 1 | 2021 | 7 | 0.050 |
Why?
| | Antibody Specificity | 1 | 2021 | 8 | 0.050 |
Why?
| | Cross Reactions | 1 | 2021 | 8 | 0.050 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 8 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2021 | 14 | 0.050 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.050 |
Why?
| | Bacteria | 1 | 2021 | 9 | 0.050 |
Why?
| | Microtubules | 2 | 1999 | 5 | 0.050 |
Why?
| | Comorbidity | 1 | 2021 | 56 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2021 | 34 | 0.050 |
Why?
| | Immunization | 1 | 2021 | 25 | 0.050 |
Why?
| | Neck | 2 | 2013 | 8 | 0.050 |
Why?
| | Dialysis Solutions | 1 | 2021 | 19 | 0.050 |
Why?
| | Catheters, Indwelling | 1 | 2021 | 31 | 0.050 |
Why?
| | Transcriptome | 1 | 2021 | 59 | 0.050 |
Why?
| | Catheterization | 1 | 2021 | 29 | 0.050 |
Why?
| | Self Care | 1 | 2021 | 22 | 0.050 |
Why?
| | Skin | 1 | 2020 | 15 | 0.050 |
Why?
| | Family Characteristics | 1 | 2020 | 10 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2020 | 20 | 0.050 |
Why?
| | Vacuoles | 1 | 2000 | 1 | 0.040 |
Why?
| | Glycosylphosphatidylinositols | 1 | 2000 | 1 | 0.040 |
Why?
| | Liver | 1 | 2021 | 126 | 0.040 |
Why?
| | RNA, Ribosomal, 23S | 1 | 2019 | 1 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 1999 | 7 | 0.040 |
Why?
| | Cytoskeleton | 1 | 1999 | 6 | 0.040 |
Why?
| | Medically Uninsured | 1 | 2019 | 5 | 0.040 |
Why?
| | Premature Birth | 1 | 2019 | 6 | 0.040 |
Why?
| | Netherlands | 1 | 2019 | 4 | 0.040 |
Why?
| | Australia | 1 | 2019 | 10 | 0.040 |
Why?
| | Regression Analysis | 1 | 2018 | 52 | 0.040 |
Why?
| | Metabolic Diseases | 1 | 2018 | 11 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 348 | 0.040 |
Why?
| | Practice Patterns, Nurses' | 1 | 2017 | 5 | 0.040 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2017 | 1 | 0.040 |
Why?
| | beta-Lactam Resistance | 1 | 2017 | 1 | 0.040 |
Why?
| | Fimbriae Proteins | 1 | 2017 | 1 | 0.040 |
Why?
| | Penicillin-Binding Proteins | 1 | 2016 | 2 | 0.040 |
Why?
| | Pharmacy Service, Hospital | 1 | 2016 | 8 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 85 | 0.040 |
Why?
| | Sequence Homology | 1 | 2015 | 2 | 0.030 |
Why?
| | Genome, Viral | 1 | 2015 | 4 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2015 | 6 | 0.030 |
Why?
| | China | 1 | 2015 | 9 | 0.030 |
Why?
| | Dyspnea | 1 | 2015 | 4 | 0.030 |
Why?
| | Colorado | 1 | 2015 | 9 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2015 | 6 | 0.030 |
Why?
| | Cough | 1 | 2015 | 7 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2015 | 17 | 0.030 |
Why?
| | Emergency Medical Services | 1 | 2015 | 14 | 0.030 |
Why?
| | Primary Health Care | 1 | 2015 | 42 | 0.030 |
Why?
| | Clinical Laboratory Services | 1 | 2015 | 2 | 0.030 |
Why?
| | Economics, Hospital | 1 | 2015 | 3 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2015 | 10 | 0.030 |
Why?
| | Cost Savings | 1 | 2015 | 10 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 99 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 90 | 0.030 |
Why?
| | Program Evaluation | 1 | 2015 | 45 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2015 | 38 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 50 | 0.030 |
Why?
| | Drainage | 1 | 2013 | 36 | 0.030 |
Why?
| | Rats | 2 | 2005 | 106 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2013 | 45 | 0.030 |
Why?
| | Diagnostic Test Approval | 1 | 2011 | 1 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2011 | 4 | 0.020 |
Why?
| | Tympanic Membrane | 1 | 2011 | 1 | 0.020 |
Why?
| | Prosthesis Failure | 1 | 2011 | 2 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 5 | 0.020 |
Why?
| | Otitis Media with Effusion | 1 | 2011 | 3 | 0.020 |
Why?
| | Administration, Oral | 1 | 2011 | 58 | 0.020 |
Why?
| | Recurrence | 1 | 2011 | 110 | 0.020 |
Why?
| | Cell Wall | 1 | 2010 | 1 | 0.020 |
Why?
| | Mycolic Acids | 1 | 2010 | 1 | 0.020 |
Why?
| | Pigments, Biological | 1 | 2010 | 1 | 0.020 |
Why?
| | Chaperonin 60 | 1 | 2010 | 1 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2010 | 3 | 0.020 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2010 | 2 | 0.020 |
Why?
| | Africa | 1 | 2010 | 3 | 0.020 |
Why?
| | Enzymes | 1 | 2010 | 4 | 0.020 |
Why?
| | Hot Temperature | 1 | 2010 | 6 | 0.020 |
Why?
| | Binding Sites | 2 | 2002 | 26 | 0.020 |
Why?
| | Bacterial Adhesion | 2 | 1999 | 2 | 0.020 |
Why?
| | Face | 1 | 2008 | 3 | 0.020 |
Why?
| | Cefoxitin | 1 | 2006 | 1 | 0.020 |
Why?
| | Doxycycline | 1 | 2006 | 1 | 0.020 |
Why?
| | Hydroxyurea | 1 | 2006 | 1 | 0.020 |
Why?
| | Linezolid | 1 | 2006 | 2 | 0.020 |
Why?
| | Ciprofloxacin | 1 | 2006 | 3 | 0.020 |
Why?
| | Acetamides | 1 | 2006 | 2 | 0.020 |
Why?
| | Oxazolidinones | 1 | 2006 | 2 | 0.020 |
Why?
| | Clarithromycin | 1 | 2006 | 3 | 0.020 |
Why?
| | Mycobacterium fortuitum | 1 | 2006 | 2 | 0.020 |
Why?
| | Amikacin | 1 | 2006 | 3 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 35 | 0.020 |
Why?
| | Uterine Diseases | 1 | 2005 | 1 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2005 | 1 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2002 | 7 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 14 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2002 | 14 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2002 | 19 | 0.010 |
Why?
| | DNA, Kinetoplast | 1 | 2002 | 1 | 0.010 |
Why?
| | Antibodies | 1 | 2002 | 15 | 0.010 |
Why?
| | Antibodies, Protozoan | 1 | 2002 | 3 | 0.010 |
Why?
| | Protein Binding | 1 | 2002 | 31 | 0.010 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2002 | 3 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2002 | 24 | 0.010 |
Why?
| | Gene Expression | 1 | 2002 | 67 | 0.010 |
Why?
| | Blood Group Antigens | 1 | 2001 | 1 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2001 | 4 | 0.010 |
Why?
| | Intestinal Diseases | 1 | 2001 | 4 | 0.010 |
Why?
| | Hemagglutinins | 1 | 2001 | 1 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2001 | 14 | 0.010 |
Why?
| | Neisseria gonorrhoeae | 1 | 1999 | 1 | 0.010 |
Why?
| | Complement C1q | 1 | 1999 | 3 | 0.010 |
Why?
| | Cattle | 1 | 1999 | 24 | 0.010 |
Why?
| | Actins | 1 | 1999 | 5 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 48 | 0.010 |
Why?
| | Cytochalasin D | 1 | 1997 | 1 | 0.010 |
Why?
| | Nocodazole | 1 | 1997 | 1 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1997 | 5 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1997 | 48 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Physical Neighbors People whose addresses are nearby this person. _
|